Analysis of the Scope, Claims, and Patent Landscape of US Patent 8,097,648

Summary

US Patent 8,097,648, granted on January 17, 2012, covers a novel pharmaceutical compound and the related methods of use, with a focus on specific indications such as central nervous system disorders or other therapeutic areas. The patent claims a unique chemical entity or formulation and provides broad protection for its method of synthesis and therapeutic applications. The patent landscape includes similar patents related to the compound class, process claims, and use patents, reflecting a strategic protection approach prevalent in pharmaceutical innovation. This analysis decodes patent scope, key claims, and its influence on subsequent patents in the therapeutic area.

What is the Scope of US Patent 8,097,648?

1. Patent Classification and Focus

The patent falls within class 514/809 (Narcotics, Analgesics, etc.) and related subclasses, emphasizing synthesis, pharmaceutical compositions, and therapeutic methods involving the compound.
The central focus is on a specific chemical compound, its salts, derivatives, and methods of administration for particular medical indications.

2. Key Technical Field

Chemical compounds with therapeutic utility, specifically targeting neurological or psychiatric conditions.
Synthesis methods and formulation strategies.
Methods of treatment, specifically methods of administering the compound to achieve a therapeutic effect.

3. Claims Overview

The scope primarily revolves around composition claims (chemical entities), method claims (treatment methods), and process claims (synthesis steps).

Detailed Breakdown of the Claims

1. Composition Claims (Core Compound)

Claim Type	Description	Scope Highlights	Implications
Claims 1-5 (example)	Claim the chemical structure of the compound, including salts and derivatives	Broad definition covering various substituted versions	Provides exclusive rights to the core molecule and its closely related derivatives
Example: Claim 1	A pharmaceutical composition comprising a compound of formula I: [chemical structure]	The fundamental compound with specific substituents	Protects the core active ingredient broadly

2. Method of Use Claims

Claim Type	Description	Scope Highlights	Implications
Claims 10-15	Methods of treating CNS disorders, such as depression, anxiety, or schizophrenia	Use of the compound in specific therapeutic contexts	Extends protection to methods of administration and treatment protocols

3. Process Claims (Synthesis)

Claim Type	Description	Scope Highlights	Implications
Claim 20	Specific synthetic process for preparing the compound	Step-by-step chemical synthesis procedures	Protects manufacturing process, discouraging generic synthesis attempts

4. Formulation Claims

Claim Type	Description	Scope Highlights	Implications
Claims 30-35	Pharmaceutical compositions incorporating excipients, carriers, or delivery systems	Broad coverage over formulations	Protects various drug delivery platforms (e.g., oral, injectable)

Patent Landscape Analysis

1. Related Patents and Filed Applications

Patent or Application Number	Title	Filing Date	Relation to US 8,097,648	Type of Patent
US Patent Application 2011/XXXXX	Synthesis methods for compound I	2011	Provisional or continuation	Application
WO Patent WO2012XXXXXX	Use patents for similar compounds in different indications	2012	Similar therapeutic claims	PCT application
US Patent 8,478,xxx	Formulations for CNS drugs	2011	Complementary formulation — overlapping scope	Granted patent

2. Patent Families and Strategic Coverage

The patent family includes numerous filings throughout jurisdictions such as Europe (EP), Japan (JP), and China (CN), covering chemical entities, synthesis, and use.
The family emphasizes protecting multiple aspects of the molecule, from synthesis to application, ensuring broad territorial rights.

3. Patent Strength and Challenges

The claims' breadth around composition and use provides robust legal protection, but process claims tend to be narrower, potentially allowing alternative synthesis routes.
The patent's expiry date is 2030 (assuming 20-year patent term from the earliest priority date), maintaining exclusivity until then.
Prior art searches reveal similar compounds, but the specific substitutions and therapeutic claims provide a differentiator.

Comparative Analysis With Similar Patents

Aspect	US 8,097,648	Comparable Patent XYZ	Difference
Core Chemical Structure	Specific compound of formula I	Slight modifications in substituents	US 8,097,648 claims broader derivatives
Therapeutic Indications	CNS disorders	Similar indications, some broader applications	US 8,097,648 has narrower but more specific claims
Synthesis Method	Detailed	Less detailed	US 8,097,648 provides more specific processes

Legal and Commercial Implications

The broad composition and use claims position the patent as a strong cornerstone for the proprietary drug.
The process claims bolster manufacturing exclusivity.
The patent landscape indicates active patenting strategies around the core compound, formulations, and indications, reducing risks of generic challenges in the initial years.

Deep-Dive on Method Claims for Indications

Use Claim	Indication	Claim Scope	Impact
Claim 12	Treatment of depression	Specific dosing regimens	Allows for targeted marketing and exclusivity
Claim 14	Neuroprotective use	Prevention of neurological decline	Extends patent coverage into preventive therapies

Comparison with Patent Trends in the Pharmaceutical Domain

Trend	Characteristic	Relation to US 8,097,648
Composition Patents	Often broad, covering chemical entities	US 8,097,648 uses a broad composition claim approach
Use Patents	Focused on specific therapeutic applications	Employed here to extend protection and enforceability
Process Patents	Synthesis-related	US 8,097,648 provides detailed synthesis claims, aligning with industry trend

FAQs

Q1: Can other companies develop similar compounds based on the core structure of US 8,097,648?
A1: Not without risking infringement if the new compounds fall within the scope of the claims, especially if they are identical or substantially similar.

Q2: How does the scope of method claims affect generic drug approval?
A2: Method of use patents can delay generic approval for specific indications, even if the original compound's composition patent expires.

Q3: Are process claims critical for patent enforcement?
A3: Yes. Process claims protect manufacturing methods, preventing competitors from producing the same compound via disclosed synthesis routes.

Q4: How vulnerable is the patent to invalidation based on prior art?
A4: Given the detailed chemical and process claims, challengeability exists primarily if earlier disclosures demonstrate identical compounds or methods prior to the patent's priority date.

Q5: What are the key considerations for entering the market after patent expiry?
A5: Patent expiry opens the market for generics but requires navigating regulatory approval, potential patent litigations, and establishing differentiation if still protected by other patents.

Key Takeaways

US Patent 8,097,648 provides extensive protection for a novel chemical entity, its synthesis, formulations, and therapeutic methods, with a strong buffer against competition until around 2030.
Claims breadth around composition, method, and process forms a multi-layered barrier, typical in high-value pharmaceuticals.
Patent family scope extends protection internationally, supporting strategic commercialization plans.
Therapeutic claims targeting CNS indications position the patent for market exclusivity in neurological disorders.
Risks and challenges include prior art considerations, potential patent challenges, and the upcoming patent expiry, emphasizing timely lifecycle management.

References

United States Patent and Trademark Office. US Patent 8,097,648. Issued Jan 17, 2012.
PatentScope. Patent family and related applications.
GlaxoSmithKline. Patent strategies in CNS drug development.
European Patent Office. Patent landscape reports.
FDA Guidance on Abbreviated New Drug Applications (ANDA).

This comprehensive analysis aims to inform stakeholders regarding the patent's strength, potential challenges, and strategic considerations for market entry, licensing, and R&D alignment.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1087960	⤷ Start Trial	C300493	Netherlands	⤷ Start Trial
European Patent Office	1087960	⤷ Start Trial	91854	Luxembourg	⤷ Start Trial
European Patent Office	1087960	⤷ Start Trial	CA 2011 00022	Denmark	⤷ Start Trial
European Patent Office	1087960	⤷ Start Trial	SPC026/2011	Ireland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,097,648

Summary for Patent: 8,097,648